Bausch + Lomb is free-cash-flow positive with a perfect 9/9 Piotroski score and strong momentum after a +54.7% earnings beat, but price is 5.9% above the analyst target and the business is concentrated in vision care with limited-source suppliers.
Thesis pillars
- Fcf Positive Despite Gaap Loss↑Improving
- Earnings Beat Momentum↑Improving
- Price Above Analyst Target→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Feb 18, 2026
Bausch + Lomb Corporation (BLCO) Stock Analysis
Healthcare · Medical Instruments & Supplies
Sell if holding. At $20.60, A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources.
Bausch + Lomb makes contact lenses, ophthalmic pharmaceuticals, surgical equipment, and consumer eye care products across three segments — Vision Care (57% of 2025 revenue), Pharmaceuticals (25%), and Surgical (18%) — with a presence in roughly 100 countries. The company... Read more
Sell if holding. At $20.60, A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.5/10, moderate confidence.
Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 103d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated Oct 27, 2026Recent Developments — Bausch + Lomb Corporation
Latest news
- NEWS Bausch + Lomb (BLCO) reports Q3: everything you need to know ahead of earnings - Yahoo Finance — Yahoo Finance Oct 27, 2026 neutral
- NEWS Bausch + Lomb (BLCO) reports Q3: everything you need to know ahead of earnings - TradingView — TradingView Oct 27, 2026 neutral
- NEWS Did CEO Exit Just Shift Bausch + Lomb (BLCO) Investment Narrative? - Yahoo Finance — Yahoo Finance Oct 25, 2026 negative
- NEWS Billionaire Investor Took a Stake in Bausch + Lomb Before Its CEO Shake-Up - Yahoo Finance — Yahoo Finance Oct 22, 2026 neutral
- NEWS Bausch & Lomb Earnings: Momentum in Implantables and Pharmaceuticals Shows Off Investment Dividends - Morningstar — Morningstar Jul 29, 2026 positive
Latest item Oct 27, 2026 · Generated 2026-11-05T11:49:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductVision Care segment57%10-K Item 1: 'Vision Care | | $ | 2,923 | | | 57 | % ... Total revenues | | $ | 5,101 | | | 100 | %'
- HIGHSuppliersingle source or limited number of sources10-K Item 1A: 'Certain of our products or components thereof are available from a single source or a limited number of sources'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $20.60, A.R:R is negative (-0.6) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $19.16. Score 5.5/10, moderate confidence.
Analyst target $18.89 reached (−8.3% from $20.60); no take-profit level is published. Prior stop was $19.16. Stop-loss: $19.16.
Concentration risk — Product: Vision Care segment (57.0%); Concentration risk — Supplier: single source or limited number of sources; Analyst target reached - limited upside remaining.
Bausch + Lomb Corporation trades at a P/E of N/A (forward 17.3). TrendMatrix value score: 6.9/10. Verdict: Sell.
19 analysts rate BLCO, with a consensus score of 3.7/5. 14 analysts publish price targets averaging $22.
What does Bausch + Lomb Corporation do?Bausch + Lomb makes contact lenses, ophthalmic pharmaceuticals, surgical equipment, and consumer eye care products...
Bausch + Lomb makes contact lenses, ophthalmic pharmaceuticals, surgical equipment, and consumer eye care products across three segments — Vision Care (57% of 2025 revenue), Pharmaceuticals (25%), and Surgical (18%) — with a presence in roughly 100 countries. The company generated $5.1 billion in total revenues in 2025 across approximately 13,000 employees globally.